Padagis US LLC
Padagis US LLC (United States) holds 1 active US FDA Type II Drug Master File, has DMF or CEP filings on record for 1 active ingredient and holds 1 active Type IV (excipient) Drug Master File. 17 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Padagis US LLC: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/padagis-us-llc
Overview
Padagis US LLC is a leading company in the pharmaceutical industry, specializing in the development and manufacturing of high-quality generic and specialty pharmaceutical products. The company is known for its focus on a diverse range of therapeutic areas, delivering affordable medicines to the market.
Core services & business areas
Therapeutic areas
Active ingredients with DMF or CEP filings
Substances for which Padagis US LLC holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
Padagis US LLC holds 1 active (1 total) FDA Type II Drug Master File. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- CONJUGATED ESTROGENS (F00022)Active1999-03-31
Excipient Drug Master Files
Padagis US LLC holds 1 active (1 total) FDA Type IV Drug Master File. A Type IV DMF covers an excipient, colourant or flavour, not an active ingredient; these are counted separately from the API filings above.
- ORA-BRAND OF ORAL PHARMACEUTICAL VEHICLESActive1999-10-08
FDA compliance signals
17 FDA enforcement records linked to this company.
- recall — Class II2026-07-22
Subpotent Drug: Low out of specification assay results performed during long-term stability testing.
- 4832026-04-08
Written sanitation procedures not followed
- 4832026-04-08
Scientifically sound laboratory controls
- 4832026-04-08
Absence of Written Procedures
- 4832026-04-08
Stability sample storage conditions described
- recall — Class II2025-03-05
Defective Container: Some packets may not be fully sealed, potentially allowing for loss of Ethanol from the product.
- recall — Class III2024-11-27
Subpotent and Superpotent Drug. Out of specification assay results recorded as part of Uniformity of Container test during long-term stability testing.
- 4832024-09-06
Cleaning SOP/inspection
- recall — Class II2023-12-13
Failed Tablets/Capsules specifications; missing/broken/extra tablets within the capsules
- recall — Class II2023-11-08
Incorrect Product Formulation: Hydrophilic Colloidal Silica was used to manufacture the product rather than Hydrophobic Colloidal Silica as required by the manufacturing process.
- recall — Class III2023-03-22
Failed Content Uniformity Specifications: The Spray Content Uniformity (SCU) requirement for Standard Deviation did not meet the requirement at the 18-month stability time point.
- recall — Class II2022-09-07
CGMP Deviations: Product complaints reporting the product to have a gritty texture and lack of effectiveness.
- 4832022-02-18
Authority lacking to review records, investigate errors
- 4832022-02-18
Procedures not in writing, fully followed
- 4832022-02-18
Procedures To Be in Writing
- recall — Class II2022-01-19
Defective Delivery System
- warning_letter2010-03-01
FDA Warning Letter (drug product)
Is this Padagis US LLC?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.